JP2017506640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506640A5 JP2017506640A5 JP2016551824A JP2016551824A JP2017506640A5 JP 2017506640 A5 JP2017506640 A5 JP 2017506640A5 JP 2016551824 A JP2016551824 A JP 2016551824A JP 2016551824 A JP2016551824 A JP 2016551824A JP 2017506640 A5 JP2017506640 A5 JP 2017506640A5
- Authority
- JP
- Japan
- Prior art keywords
- edc
- alkyl
- present
- targeting moiety
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 230000008685 targeting Effects 0.000 claims description 16
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 12
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 10
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 10
- 150000003431 steroids Chemical class 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- QEEBRPGZBVVINN-UHFFFAOYSA-N Desacetyl-bufotalin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C1(O)CCC2C=1C=CC(=O)OC=1 QEEBRPGZBVVINN-UHFFFAOYSA-N 0.000 claims description 4
- QEEBRPGZBVVINN-BMPKRDENSA-N bufalin Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC4)C)CC[C@@]32C)C=CC(=O)OC=1 QEEBRPGZBVVINN-BMPKRDENSA-N 0.000 claims description 4
- 230000003177 cardiotonic effect Effects 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- TYYDXNISHGVDGA-UHFFFAOYSA-N Corotoxigenin Natural products CC12CCC3C(CCC4CC(O)CCC34C=O)C1CCC2C5=CC(=O)OC5 TYYDXNISHGVDGA-UHFFFAOYSA-N 0.000 claims description 3
- JIUWTCXNUNHEGP-GJHPUSIBSA-N cardenolide Chemical compound C1([C@H]2CC[C@@H]3[C@H]4[C@@H]([C@]5(CCCCC5CC4)C)CC[C@@]32C)=CC(=O)OC1 JIUWTCXNUNHEGP-GJHPUSIBSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- XZTUSOXSLKTKJQ-UHFFFAOYSA-N Uzarigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C1(O)CCC2C1=CC(=O)OC1 XZTUSOXSLKTKJQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 229960002204 daratumumab Drugs 0.000 claims description 2
- XZTUSOXSLKTKJQ-CESUGQOBSA-N digitoxigenin Chemical compound C1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC4)C)CC[C@@]32C)=CC(=O)OC1 XZTUSOXSLKTKJQ-CESUGQOBSA-N 0.000 claims description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461940219P | 2014-02-14 | 2014-02-14 | |
| US61/940,219 | 2014-02-14 | ||
| US201461946314P | 2014-02-28 | 2014-02-28 | |
| US61/946,314 | 2014-02-28 | ||
| PCT/US2015/016212 WO2015123687A1 (en) | 2014-02-14 | 2015-02-17 | Extracellular targeted drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017506640A JP2017506640A (ja) | 2017-03-09 |
| JP2017506640A5 true JP2017506640A5 (enExample) | 2018-03-08 |
Family
ID=53800709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551824A Pending JP2017506640A (ja) | 2014-02-14 | 2015-02-17 | 細胞外標的化薬物共役体 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US10675352B2 (enExample) |
| EP (1) | EP3104882B1 (enExample) |
| JP (1) | JP2017506640A (enExample) |
| WO (1) | WO2015123687A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3328393B1 (en) | 2015-07-31 | 2023-12-20 | Centrose, Llc | Extracellular drug conjugates targeting cd20 |
| EP3413874A4 (en) * | 2016-02-12 | 2020-01-22 | Mayo Foundation for Medical Education and Research | TREATMENTS FOR BLOOD CANCER |
| CN110997722B (zh) | 2017-06-08 | 2023-09-26 | 黑带医疗有限公司 | Cd38调节抗体 |
| JP7679196B2 (ja) | 2017-06-08 | 2025-05-19 | ブラック ベルト セラピューティクス リミテッド | Ｃｄ３８調節抗体 |
| JP7359700B2 (ja) * | 2017-06-20 | 2023-10-11 | ソレント・セラピューティクス・インコーポレイテッド | Ｃｄ３８抗体薬物コンジュゲート |
| BR112021009750A2 (pt) | 2018-12-20 | 2021-08-17 | Kleo Pharmaceuticals, Inc | terapia de combinação de arms e células exterminadoras naturais |
| US20230028880A1 (en) * | 2019-07-03 | 2023-01-26 | Biohaven Therapeutics Ltd. | Cd38-binding agents and uses thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4364935A (en) | 1979-12-04 | 1982-12-21 | Ortho Pharmaceutical Corporation | Monoclonal antibody to a human prothymocyte antigen and methods of preparing same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| EP0626012B1 (en) | 1992-02-11 | 2003-07-09 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| EP0616812B1 (en) | 1993-03-24 | 1999-11-03 | Berlex Biosciences | Combination with anti-hormonal compounds and binding molecules for the treatment of cancer |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
| MX9800684A (es) | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| AU5241100A (en) | 1999-09-28 | 2001-04-30 | Universitat Zurich | Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis |
| DK1272647T3 (en) | 2000-04-11 | 2014-12-15 | Genentech Inc | Multivalent antibodies and uses thereof |
| EP1174440A1 (en) * | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| NZ538996A (en) | 2002-10-31 | 2008-04-30 | Genentech Inc | Methods and compositions for increasing antibody production |
| AU2004205684A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| EA015584B1 (ru) * | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| JP2009507228A (ja) * | 2005-08-31 | 2009-02-19 | アフィーマックス・インコーポレイテッド | プロキシマーカーを用いる生物学的流体およびその他の溶液マトリックス中の薬物の誘導体化および低レベル検出 |
| WO2007140282A1 (en) * | 2006-05-24 | 2007-12-06 | Peg Biosciences | Peg linker compounds and biologically active conjugates thereof |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CN101520150A (zh) | 2008-04-08 | 2009-09-02 | 王跃农 | 一种方便型节能吸顶灯 |
| US20100017480A1 (en) | 2008-07-17 | 2010-01-21 | International Business Machines Corporation | Recipient side grouping of addresses |
| US20120122514A1 (en) | 2008-10-23 | 2012-05-17 | Qualcomm Incorporated | Selecting network service providers for multi-mode mobile devices |
| US8367419B2 (en) | 2009-06-25 | 2013-02-05 | Rutgers, The State University Of New Jersey | Compositions and methods for detection of explosives |
| CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
| EP2580243B1 (en) * | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| LT2621531T (lt) * | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| US20140088056A1 (en) | 2010-09-28 | 2014-03-27 | President And Fellows Of Harvard College | Cardiac glycosides are potent inhibitors of interferon-beta gene expression |
| CA2819635A1 (en) * | 2010-12-01 | 2012-06-07 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CN103732259A (zh) * | 2011-06-24 | 2014-04-16 | 森彻斯有限公司 | 细胞外靶向药物缀合物 |
| BR112014013526A8 (pt) | 2011-12-05 | 2017-06-13 | Igenica Biotherapeutics Inc | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados |
| EP3328393B1 (en) * | 2015-07-31 | 2023-12-20 | Centrose, Llc | Extracellular drug conjugates targeting cd20 |
| US20170049908A1 (en) * | 2015-08-17 | 2017-02-23 | Centrose, Llc | Extracellular targeted drug conjugates |
-
2015
- 2015-02-17 JP JP2016551824A patent/JP2017506640A/ja active Pending
- 2015-02-17 EP EP15749237.2A patent/EP3104882B1/en active Active
- 2015-02-17 US US15/117,672 patent/US10675352B2/en active Active
- 2015-02-17 WO PCT/US2015/016212 patent/WO2015123687A1/en not_active Ceased
-
2020
- 2020-03-25 US US16/830,049 patent/US20200384122A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506640A5 (enExample) | ||
| JP2013505944A5 (enExample) | ||
| JP2011500725A5 (enExample) | ||
| JP2016506916A5 (enExample) | ||
| JP2017518302A5 (enExample) | ||
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2014521688A5 (enExample) | ||
| MX2019009255A (es) | Proteínas quiméricas dirigidas y sus usos. | |
| JP2016508130A5 (enExample) | ||
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| JP2015527318A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2019503387A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| WO2009082818A8 (en) | Novel c-21-keto lupane derivatives preparation and use thereof | |
| CY1119231T1 (el) | Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3 | |
| JP2015519389A5 (enExample) | ||
| JP2012102122A5 (enExample) | ||
| CA2896976A1 (en) | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | |
| JP2017503014A5 (enExample) | ||
| JP2019533651A5 (enExample) | ||
| JP2019519593A5 (enExample) | ||
| WO2012177653A3 (en) | Targeting the neuromuscular junction for treatment | |
| JP2019507764A5 (enExample) |